Epibatidine

DB07720

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 208.687
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

121 Data
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Epibatidine.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Epibatidine.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Epibatidine.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Epibatidine.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Epibatidine.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Epibatidine.
Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Epibatidine.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Epibatidine.
Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Epibatidine.
Alprenolol The risk or severity of adverse effects can be increased when Alprenolol is combined with Epibatidine.
Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Epibatidine.
Carvedilol The risk or severity of adverse effects can be increased when Carvedilol is combined with Epibatidine.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Epibatidine.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Epibatidine.
Nadolol The risk or severity of adverse effects can be increased when Nadolol is combined with Epibatidine.
Bevantolol The risk or severity of adverse effects can be increased when Bevantolol is combined with Epibatidine.
Practolol The risk or severity of adverse effects can be increased when Practolol is combined with Epibatidine.
Penbutolol The risk or severity of adverse effects can be increased when Penbutolol is combined with Epibatidine.
Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Epibatidine.
Dexpropranolol The risk or severity of adverse effects can be increased when Dexpropranolol is combined with Epibatidine.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Epibatidine.
Nebivolol The risk or severity of adverse effects can be increased when Nebivolol is combined with Epibatidine.
Bufuralol The risk or severity of adverse effects can be increased when Bufuralol is combined with Epibatidine.
Bopindolol The risk or severity of adverse effects can be increased when Bopindolol is combined with Epibatidine.
Bupranolol The risk or severity of adverse effects can be increased when Bupranolol is combined with Epibatidine.
Indenolol The risk or severity of adverse effects can be increased when Indenolol is combined with Epibatidine.
Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Epibatidine.
Levobetaxolol The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Epibatidine.
Talinolol The risk or severity of adverse effects can be increased when Talinolol is combined with Epibatidine.
Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Epibatidine.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Epibatidine.
Esatenolol The risk or severity of adverse effects can be increased when Esatenolol is combined with Epibatidine.
Cloranolol The risk or severity of adverse effects can be increased when Cloranolol is combined with Epibatidine.
Mepindolol The risk or severity of adverse effects can be increased when Mepindolol is combined with Epibatidine.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Epibatidine.
Tertatolol The risk or severity of adverse effects can be increased when Tertatolol is combined with Epibatidine.
Landiolol The risk or severity of adverse effects can be increased when Landiolol is combined with Epibatidine.
Cimetropium Epibatidine may decrease the anticholinergic activities of Cimetropium.
Pegvisomant The risk or severity of adverse effects can be increased when Pegvisomant is combined with Epibatidine.
Mefloquine The risk or severity of adverse effects can be increased when Mefloquine is combined with Epibatidine.
Tacrine The risk or severity of adverse effects can be increased when Tacrine is combined with Epibatidine.
Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Epibatidine.
Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Epibatidine.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Epibatidine.
Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Epibatidine.
Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Epibatidine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Epibatidine.
Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Epibatidine.
Pyridostigmine The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Epibatidine.
Nizatidine The risk or severity of adverse effects can be increased when Nizatidine is combined with Epibatidine.
Galantamine The risk or severity of adverse effects can be increased when Galantamine is combined with Epibatidine.
Isoflurophate The risk or severity of adverse effects can be increased when Isoflurophate is combined with Epibatidine.
Diethylcarbamazine The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Epibatidine.
Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Epibatidine.
Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Epibatidine.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Epibatidine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Epibatidine.
Hexafluronium The risk or severity of adverse effects can be increased when Hexafluronium is combined with Epibatidine.
Demecarium The risk or severity of adverse effects can be increased when Demecarium is combined with Epibatidine.
Physostigmine The risk or severity of adverse effects can be increased when Physostigmine is combined with Epibatidine.
Rivastigmine The risk or severity of adverse effects can be increased when Rivastigmine is combined with Epibatidine.
Edrophonium The risk or severity of adverse effects can be increased when Edrophonium is combined with Epibatidine.
Procainamide The risk or severity of adverse effects can be increased when Procainamide is combined with Epibatidine.
Memantine The risk or severity of adverse effects can be increased when Memantine is combined with Epibatidine.
Ambenonium The risk or severity of adverse effects can be increased when Ambenonium is combined with Epibatidine.
Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Epibatidine.
Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Epibatidine.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Epibatidine.
Decamethonium The risk or severity of adverse effects can be increased when Decamethonium is combined with Epibatidine.
Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Epibatidine.
Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Epibatidine.
Ginkgo biloba The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Epibatidine.
Neostigmine The risk or severity of adverse effects can be increased when Neostigmine is combined with Epibatidine.
Bambuterol The risk or severity of adverse effects can be increased when Bambuterol is combined with Epibatidine.
1,10-Phenanthroline The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Epibatidine.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Epibatidine.
Huperzine A The risk or severity of adverse effects can be increased when Huperzine A is combined with Epibatidine.
Phenserine The risk or severity of adverse effects can be increased when Phenserine is combined with Epibatidine.
Regramostim The risk or severity of adverse effects can be increased when Regramostim is combined with Epibatidine.
Aprotinin The risk or severity of adverse effects can be increased when Aprotinin is combined with Epibatidine.
Betaine The risk or severity of adverse effects can be increased when Betaine is combined with Epibatidine.
Capsaicin The risk or severity of adverse effects can be increased when Capsaicin is combined with Epibatidine.
Coumaphos The risk or severity of adverse effects can be increased when Coumaphos is combined with Epibatidine.
Dichlorvos The risk or severity of adverse effects can be increased when Dichlorvos is combined with Epibatidine.
Fenthion The risk or severity of adverse effects can be increased when Fenthion is combined with Epibatidine.
Metrifonate The risk or severity of adverse effects can be increased when Metrifonate is combined with Epibatidine.
Acotiamide The risk or severity of adverse effects can be increased when Acotiamide is combined with Epibatidine.
Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Epibatidine.
Paraoxon The risk or severity of adverse effects can be increased when Paraoxon is combined with Epibatidine.
Tyrothricin The risk or severity of adverse effects can be increased when Tyrothricin is combined with Epibatidine.
Ipidacrine The risk or severity of adverse effects can be increased when Ipidacrine is combined with Epibatidine.
Distigmine The risk or severity of adverse effects can be increased when Distigmine is combined with Epibatidine.
Tretamine The risk or severity of adverse effects can be increased when Tretamine is combined with Epibatidine.
Posiphen The risk or severity of adverse effects can be increased when Posiphen is combined with Epibatidine.
Methylphosphinic Acid The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Epibatidine.
Capreomycin The therapeutic efficacy of Epibatidine can be decreased when used in combination with Capreomycin.
Framycetin The therapeutic efficacy of Epibatidine can be decreased when used in combination with Framycetin.
Amikacin The therapeutic efficacy of Epibatidine can be decreased when used in combination with Amikacin.
Tobramycin The therapeutic efficacy of Epibatidine can be decreased when used in combination with Tobramycin.
Gentamicin The therapeutic efficacy of Epibatidine can be decreased when used in combination with Gentamicin.

Target Protein

CHRNA7-FAM7A fusion protein CHRFAM7A
Neuronal acetylcholine receptor subunit alpha-7 CHRNA7
Neuronal acetylcholine receptor subunit beta-2 CHRNB2
Neuronal acetylcholine receptor subunit alpha-2 CHRNA2
Neuronal acetylcholine receptor subunit alpha-3 CHRNA3
Neuronal acetylcholine receptor subunit alpha-4 CHRNA4
Neuronal acetylcholine receptor subunit beta-4 CHRNB4

Referensi & Sumber

Synthesis reference: Csaba Sz antay, Zsuzsanna B. Kardos, Istv an Moldvai, Eszter T. Major, Csaba Sz antay, Jr., Attila M andi, G abor Blask o, Gyula Simig, Gy orgyi Lax, S andor Drabant, Tamas Sz all asi, M arton Fekete, G abor Gigler, "Process for the preparation of epibatidine." U.S. Patent US5545741, issued March, 1994.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul